Profilin-1 (PFN1) Zoidakis et al., 2012 (6060. Zoidakis J, Makridakis M, Zerefos PG, Bitsika V, Esteban S, Frantzi M, et at. Profilin 1 is a potential biomarker for bladder cancer aggressiveness. Mol Cell Proteomics. 2012;11:M111.) |
35 patients with stage pTa-pT2 + cancer |
Prediction of invasiveness |
Decreased PFN1 expression in invasive (T2) versus high risk non-invasive (T1G3) tumors, correlation with poor prognosis and increased mortality |
Histone H2B (H2B) and Zinc finger protein 335 (NIF-1) Frantzi et al., 2013 (6161. Frantzi M, Zoidakis J, Papadopoulos T, Zürbig P, Katafigiotis I, Stravodimos K, et at. IMAC fractionation in combination with LC-MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers. J Proteome Res. 2013;12:3969-79.) |
32 patients with stage pTa-pT2+ |
Prediction of progression |
Potential marker for discriminating BC stages, association with tumor progression |
Bladder cancer-associated protein (BLCAP) Moreira et al., 2010 (6464. Moreira JM, Ohlsson G, Gromov P, Simon R, Sauter G, Celis JE, et at. Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol Cell Proteomics. 2010;9:161-77.) |
120 bladder specimens: histologically normal or various tumor stages |
Prediction of progression, prognostic value |
Loss of BLCAP expression confers a poorer prognosis for patients |
Cystatin B (CSTB) Feldman et al., 2009 (6363. Feldman AS, Banyard J, Wu CL, McDougal WS, Zetter BR. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res. 2009;15:1024-31.) |
37 BC and 35 normal urothelial specimens |
Prediction of recurrence and progression |
Increased CSTB expression correlated with stage and grade, recurrence and progression |
Maspin Kramer et al., 2010 (6666. Kramer MW, Waalkes S, Hennenlotter J, Serth J, Stenzl A, Kuczyk MA, et at. Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer. Oncol Lett. 2010;1:621-6.) |
162 patients with stages pTa-T1 cancer (NMIBC) |
Prediction of recurrence and progression |
Low Maspin expression correlated to tumor progression and recurrence |
Carbonic anhydrase 9 (CAIX) Klatte et al., 2009 (6767. Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, et at. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer. 2009;115:1448-58.) |
340 patients with BC of all stages |
Prediction of recurrence, progression and survival |
For NMIBC, higher CAIX was associated with poorer recurrence-free survival. In MIBC patients who underwent cystectomy, higher CAIX related to worse overall survival |
Cyclin D1 (CCND1) Seiler et al., 2014 (6868. Seiler R, Thalmann GN, Rotzer D, Perren A, Fleischmann A. CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response. Mod Pathol. 2014;27:87-95.) |
152 patients who underwent radical cystectomy |
Response to adjuvant chemotherapy and survival |
High CCND1 levels associated with disease-specific survival in patients treated with adjuvant chemotherapy |
TP53, p21, p27kip1 and p107 Shariat et al., 2012 (6969. Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, et at. Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol. 2012;187:457-62.) |
324 BC patients with pT1-T2 who received radical cystectomy |
Prediction of recurrence and survival |
Increased prediction accuracy for disease recurrence and cancer specific mortality by 15.6% and 14.8%, respectively (p <0.001) |
Cathepsin E, Maspin, PLK1, survivin Fristrup et al., 2012 (7070. Fristrup N, Ulhøi BP, Birkenkamp-Demtröder K, Mansilla F, Sanchez-Carbayo M, Segersten U, et at. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol. 2012;180:1824-34.) |
693 patients with stages pTa-T1 cancer (NMIBC) |
Prediction of progression |
Expression of cathepsin E, maspin, Plk1, and survivin significantly associated with progression to stage T2-T4 bladder cancer |
Androgen receptor, JMJD2A and LSD1-AR Kauffman et al., 2011 (7171. Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, et at. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog. 2011;50:931-44.) |
72 patients who underwent radical cystectomy |
Prediction of progression and survival |
Significant reduced expression associated with cancer stage progression, muscle invasion and lymph node metastasis |